Cryptogenic Stroke: To Close a Patent Foramen Ovale or Not to Close?

Area of Science:

• Cardiology
• Neurology
• Medical Devices

Background:

• Patent foramen ovale (PFO) is common in cryptogenic stroke (CS) patients.
• The role of PFO closure versus medical therapy for CS secondary prevention is debated.
• Paradoxical embolism via PFO is a suspected cause of CS, particularly in younger individuals.

Purpose of the Study:

• To evaluate the efficacy of PFO closure compared to medical therapy for preventing recurrent strokes in CS patients.
• To address the controversy surrounding PFO management in CS.
• To analyze recent randomized controlled trials and meta-analyses on PFO closure for CS.

Main Methods:

• Review of randomized controlled trials (RCTs) and meta-analyses.
• Comparison of PFO closure (surgical or transcutaneous) with anticoagulation (antithrombin or antiplatelet) therapy.
• Analysis of studies that controlled for confounding factors and biases.

Main Results:

• Earlier trials showed no significant benefit of PFO closure.
• Recent meta-analyses and specific trials (e.g., CLOSE, REDUCE) suggest a benefit for PFO closure over medical therapy.
• These newer studies indicate PFO closure may be superior in managing CS.

Conclusions:

• Recent evidence supports PFO closure as a potentially superior strategy for secondary stroke prevention in select CS patients.
• The findings may lead to a paradigm shift in the treatment of cryptogenic strokes associated with PFO.
• Further research and clinical guidelines may evolve based on these updated trial results.